Acute Myelosuppression Secondary to Inflammatory Bowel Disease Treated with Azathioprine and Mesalazine：a Case Report and Literature Review

doi:10.12114/j.issn.1007-9572.2019.00.058

Abstract

Abstract: Azathioprine（AZA） is an immunosuppressant that inhibits lymphocyte proliferation and could be used for inflammatory bowel disease（IBD），but has a high incidence of adverse reactions.We reported a case of IBD in December 12，2017 in Gastroenterology Department of Guangzhou University of Chinese Medicine who had acute myelosuppression after being treated with oral AZA for 18 months，then AZA with mesalazine for 2 months，but relieved after our treatment.In particular，routine blood test results were analyzed in detail.By literature review，we found that such patients have been rarely reported in China，whereas widely studied in abroad.Moreover，we summarized the problems resulting from combination medications for IBD，hoping to increase clinicians' knowledge about this disease and enhance their attention to its clinical diagnosis and management.

Key words: Inflammatory bowel diseases；Azathioprine；Mesalamine；Drug therapy, combination；Myelosuppression；Case reports；Literature review

摘要： 硫唑嘌呤（AZA）是一种通过抑制淋巴细胞增殖产生免疫抑制作用的免疫抑制剂，能用于治疗炎症性肠病（IBD），但不良反应发生率高。本文对2017-12-12广东中医药大学第二临床医学院消化内科成功救治的1例口服AZA 18个月后联合应用美沙拉嗪2个月出现急性骨髓抑制的IBD患者的血常规进行分析，并查阅文献发现国内AZA联合美沙拉嗪致骨髓抑制的病例报道较少见，但国外报道较丰富，通过梳理国内外相关文献指出IBD联合用药存在的问题，以期提高临床对IBD诊疗的认识及重视。

关键词: 炎性肠疾病；硫唑嘌呤；美沙拉嗪；药物疗法, 联合；骨髓抑制；病例报告；文献复习

YANG Yuanming,ZHENG Huan,HUANG Shaogang, et al. Acute Myelosuppression Secondary to Inflammatory Bowel Disease Treated with Azathioprine and Mesalazine：a Case Report and Literature Review　[J]. Chinese General Practice, 2019, 22(23): 2893-2896. DOI: 10.12114/j.issn.1007-9572.2019.00.058.
杨元明,郑欢,黄绍刚等. 硫唑嘌呤联合美沙拉嗪治疗炎症性肠病致急性骨髓抑制一例报道并文献回顾[J]. 中国全科医学, 2019, 22(23): 2893-2896. DOI: 10.12114/j.issn.1007-9572.2019.00.058.

References

［1］戎兰.免疫抑制剂在炎症性肠病治疗中的应用［J］．上海医药，2016，37（1）：11-15.
RONG L.Application of immunosuppressants in the treatment of inflammatory bowel disease［J］．Shanghai Medical & Pharmaceutical Journal，2016，37（1）：11-15.
［2］SHI H Y，CHAN F K，LEUNG W K，et al．Low-dose azathioprine is effective in maintaining remission in steroid-dependent ulcerative colitis：results from a territory-wide Chinese population-based IBD registry［J］．Therap Adv Gastroenterol，2016，9（4）：449-456．DOI：10.1177/1756283X16643509.
［3］GOMOLLóN F，DIGNASS A，ANNESE V，et al．3rd European evidence-based consensus on the diagnosis and management of crohn's disease 2016：part 1：diagnosis and medical management［J］．J Crohns Colitis，2017，11（1）：3-25．DOI：10.1093/ecco-jcc/jjw168.
［4］黄益彪.中国炎症性肠病患者硫唑嘌呤相关副作用的特点及其危险因素—一项20年的大样本回顾性研究［D］．杭州：浙江大学，2018.
［5］赵峻，张莉蓉，乔海灵.免疫抑制剂硫唑嘌呤的药物不良反应［J］．中国误诊学杂志，2006，6（5）：839-841．DOI：10.3969/j.issn.1009-6647.2006.05.022.
［6］SUTHERLAND L，MACDONALD J K.Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis［J］．Cochrane Database Syst Rev，2006，19（2）：CD000543．DOI：10.1002/14651858.CD000543.pub2.
［7］DE GRAAF P，DE BOER N K，WONG D R，et al．Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels：a prospective study in patients under steady thiopurine therapy［J］．Br J Pharmacol，2010，160（5）：1083-1091．DOI：10.1111/j.1476-5381.2010.00731.x.
［8］陆再英，钟南山.内科学［M］．7版.北京：人民卫生出版社，2008：593.
［9］孙燕.内科肿瘤学［M］．北京：人民卫生出版社，2001：995-997.
［10］中华医学会消化病学分会炎症性肠病学组.炎症性肠病诊断与治疗的共识意见（2012年，广州）［J］．中华消化杂志，2012，32（12）：796-813．DOI：10.3760/cma.j.issn.0254-1432.2012.12.002.
Inflammatory Bowel Disease Group，Chinese Society of Gastroenterology，Chinese Medical Association.Chinese consensus on diagnosis and treatment of inflammatory bowel disease（Guangzhou，2012）［J］．Chinese Journal of Digestion，2012，32（12）：796-813．DOI：10.3760/cma.j.issn.0254-1432.2012.12.002.
［11］张声生，沈洪，郑凯，等．溃疡性结肠炎中医诊疗专家共识意见（2017）［J］．中华中医药杂志，2017，32（8）：3585-3589.
ZHANG S S，SHEN H，ZHENG K，et al．Consensus of traditional Chinese medicine on diagnosis and treatment of inflammatory bowel disease（2017）［J］．China Journal of Traditional Chinese Medicine and Pharmacy，2017，32（8）：3585-3589.
［12］中华医学会消化病学分会炎症性肠病学组.炎症性肠病诊断与治疗的共识意见（2018年，北京）［J］．中华消化杂志，2018，38（5）：292-311．DOI：10.3760/cma.j.issn.0254-1432.2018.05.002.
Inflammatory Bowel Disease Group，Chinese Society of Gastroenterology，Chinese Medical Association.Chinese consensus on diagnosis and treatment of inflammatory bowel disease（Beijing，2018）［J］．Chinese Journal of Digestion，2018，38（5）：292-311．DOI：10.3760/cma.j.issn.0254-1432.2018.05.002.
［13］乐岚，刘建平.免疫抑制剂硫唑嘌呤治疗炎性肠病不良反应分析［J］．现代实用医学，2014，26（6）：726-727．DOI：10.3969/j.issn.1671-0800.2014.06.047.
YUE L，LIU J P.Analysis of adverse reactions of immunosuppressive azathioprine in the treatment of inflammatory bowel disease［J］．Modern Practical Medicine，2014，26（6）：726-727．DOI：10.3969/j.issn.1671-0800.2014.06.047.
［14］杨黄欢.硫唑嘌呤治疗364例炎症性肠病患者致不良反应分析报告［D］．杭州：浙江大学，2016.
YANG H H.Report on adverse drug reactions analysis of azathioprine in the treatment of 364 patients with inflammatory bowel diseases［D］.Hangzhou：Zhejiang University，2016.
［15］詹钟平，杨岫岩，黄民，等．硫唑嘌呤致血液系统危象的临床特征与酶学基础［J］．中华风湿病学杂志，2005，9（3）：145-148．DOI：10.3760/j:issn:1007-7480.2005.03.005.
ZHAN Z P，YANG X Y，HUANG M，et al．Clinical characteristics and enzymology basis of hematological crisis caused by azathioprine［J］.Chinese Journal of Rheumatology，2005，9（3）：145-148.DOI：10.3760/j:issn:1007-7480.2005.03.005.
［16］陈冬莹，王晓东，詹钟平，等．硫唑嘌呤治疗系统性红斑狼疮的不良反应与硫嘌呤甲基转移酶活性的关系［J］．中山大学学报（医学科学版），2011，32（6）：777-780，785.
CHEN D Y，WANG X D，ZHAN Z P，et al．Relationship between thiopurine methyltransferase activity and azathioprine-related adverse drug reactions in maintenance therapy of systemic lupus erythematosus patients［J］．Journal of Sun Yat-Sen University（Medical Sciences），2011，32（6）：777-780，785.
［17］MAYBERRY J.The history of 5-ASA compounds and their use in ulcerative colitis--trailblazing discoveries in gastroenterology［J］．J Gastrointestin Liver Dis，2013，22（4）：375-377.
［18］杜维维，杨国栋，王应邦.炎症性肠病联合治疗的研究现状［J］．胃肠病学和肝病学杂志，2018，27（2）：227-231．DOI：10.3969/j.issn.1006-5709.2018.02.027.
DU W W，YANG G D，WANG Y B.The research statue of combination therapy for inflammatory bowel disease［J］．Chinese Journal of Gastroenterology and Hepatology，2018，27（2）：227-231．DOI：10.3969/j.issn.1006-5709.2018.02.027.
［19］GEARRY R B，AJLOUNI Y，NANDURKAR S，et al．5-aminosalicylic acid（mesalazine） use in Crohn's disease：a survey of the opinions and practice of Australian gastroenterologists［J］．Inflamm Bowel Dis，2007，13（8）：1009-1015．DOI：10.1002/ibd.20135.
［20］DE BOER N K，WONG D R，JHARAP B，et al．Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism［J］．Am J Gastroenterol，2007，102（12）：2747-2753．DOI：10.1111/j.1572-0241.2007.01511.x.
［21］NGUYEN T M，LE GALL C，LACHAUX A，et al．High thiopurine metabolite concentrations associated with lymphopenia in inflammatory bowel disease（IBD） pediatric patients receiving aminosalicylates combined with azathioprine［J］．Int J Clin Pharmacol Ther，2010，48（4）：275-281.
［22］GAO X，ZHANG F B，DING L，et al．The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients［J］．Eur J Gastroenterol Hepatol，2012，24（8）：958-964．DOI：10.1097/MEG.0b013e3283545ae3.
［23］GISBERT J P，GOMOLLóN F.Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease：a review［J］．Am J Gastroenterol，2008，103（7）：1783-1800．DOI：10.1111/j.1572-0241.2008.01848.x.
［24］BERMEJO F，GISBERT J P.Usefulness of salicylate and thiopurine coprescription in steroid-dependent ulcerative colitis and withdrawal strategies［J］．Ther Adv Chronic Dis，2010，1（3）：107-114．DOI：10.1177/2040622310374897.
［25］冯静，王雪丁，杨健，等．合用5-氨基水杨酸对炎症性肠病患者硫嘌呤类药物个体化应用的影响及其机制研究进展［J］．中国药房，2016，27（27）：3886-3888．DOI：10.6039/j.issn.1001-0408.2016.27.48.
FENG J，WANG X D，YANG J，et al．The mechanism advances and effects of 5-aminosalicylic acid on the individualized application of azathioprine in patients with inflammatory bowel disease［J］．China Pharmacy，2016，27（27）：3886-3888．DOI：10.6039/j.issn.1001-0408.2016.27.48.
［26］DE ACOSTA M B，ZABALA-FERNANDEZ W，ECHARRI A，et al．Pharmacogenetics study of TMPT and ITPA genes in patients with inflammatory bowel disease treated with azathioprine detects relation between itpase deficiency and clinical response［J］．Gastroenterol，2011，140（5）：S-769.
［27］KIM H S，CHEON J H，JUNG E S，et al．A coding variant in FTO confers susceptibility to thiopurine-induced leukopenia in East Asian patients with IBD［J］．Gut，2017，66（11）：1926-1935．DOI：10.1136/gutjnl-2016-311921.
［28］AILING Z，JING Y，JINGLI L，et al．Further evidence that a variant of the gene NUDT15 may be an important predictor of azathioprine-induced toxicity in Chinese subjects：a case report［J］．J Clin Pharm Ther，2016，41（5）：572-574．DOI：10.1111/jcpt.12420.
［29］朱琴.硫唑嘌呤治疗炎症性肠病疗效及安全性监测体系的建立［D］．杭州：浙江大学，2008.
［30］KWAK M S，KIM K J，CHEON J H，et al．Comparison of concomitant mesalamine and immunomodulator therapy and immunomodulator monotherapy for Crohn's disease［J］．Gastroenterol Res Pract，2018，2018：4826973．DOI：10.1155/2018/4826973.